The Bull Case For LivaNova (LIVN) Could Change Following Q3 Beat and Ambitious 2030 Growth Targets

• On November 18, 2025, Story Brooke, a director at LivaNova PLC, sold 250 shares following the company’s strong third-quarter results that exceeded analyst expectations for both earnings per share and revenue.
• Management also set ambitious 2030 targets, projecting high-single-digit-plus revenue growth and adjusted operating margins above 20% over the next three years, signaling a confident outlook on the company’s longer-term potential.
• We’ll explore how LivaNova’s newly announced earnings beat and 2030 growth targets might reshape the company’s investment narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

LivaNova Investment Narrative Recap

To be a shareholder in LivaNova, you need to believe in the long-term growth of advanced neuromodulation and cardiopulmonary therapies, powered by innovation and global expansion. The positive earnings surprise and raised 2030 targets strengthen momentum around the company’s short-term growth catalysts and margin expansion efforts, while risks tied to regulatory or reimbursement shifts remain largely unchanged by this news.

The recent uplift in full-year 2025 earnings and revenue guidance is particularly relevant here, reinforcing management’s confidence and aligning with the narrative of improved operating leverage and robust top-line growth as driving forces behind investor optimism.

On the other hand, investors should be aware that the company’s future could still be affected if...

Read the full narrative on LivaNova (it's free!)

LivaNova's outlook anticipates $1.6 billion in revenue and $168.9 million in earnings by 2028. This projection is based on a 6.4% annual revenue growth rate and a $380.2 million increase in earnings from the current -$211.3 million.

Uncover how LivaNova's forecasts yield a $69.00 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Two Simply Wall St Community members estimated LivaNova’s fair value between US$69 and US$176 per share. This diversity reflects how procedure growth and premium pricing assumptions can lead to widely different outlooks on LivaNova’s potential, explore these viewpoints to understand what could shape returns ahead.

Explore 2 other fair value estimates on LivaNova - why the stock might be worth just $69.00!

Build Your Own LivaNova Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your LivaNova research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Find companies with promising cash flow potential yet trading below their fair value.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com